Japanese journal of clinical oncology
-
Jpn. J. Clin. Oncol. · Sep 2013
Review Practice GuidelineClinical guideline for pharmacological management of cancer pain: the Japanese Society of Palliative Medicine recommendations.
Pain is the most frequent and distressing symptom in cancer patients. As part of a worldwide effort to improve the quality of pain control, several clinical guidelines for the management of cancer pain have been published and revised in the last decade. The Japanese Society of Palliative Medicine first published a Japanese clinical guideline for the management of cancer pain in 2000. ⋯ This review paper summarizes the recommendations and the rationales of this new clinical guideline for the pharmacological management of cancer pain. In addition, a short summary of the clinical guideline development process is provided. This new Japanese Society of Palliative Medicine guideline highlights the importance of conducting well-designed studies to identify the best practices in cancer pain management.
-
Jpn. J. Clin. Oncol. · Sep 2013
Meta AnalysisSystematic evaluation of prophylactic neck dissection for the treatment of papillary thyroid carcinoma.
The objective of the study was to evaluate the efficacy of prophylactic neck dissection in the treatment of papillary thyroid cancer and to provide guidelines for clinical practice. ⋯ Combined thyroidectomy and prophylactic neck dissection may be effective in the treatment of patients with papillary thyroid cancer, without more complications compared with thyroidectomy alone.
-
Pakistan is a lesser-developed country in South-West Asia, with a large and young population. We review here the current burden of cancer in Pakistan, followed by an assessment of the current facilities for diagnosis and treatment of cancer in the country. An effort is made to define the key problems in the delivery of optimal cancer care, and some possible solutions are offered.
-
Jpn. J. Clin. Oncol. · Jun 2013
ReviewDrug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.
Glioblastoma is a highly vascular tumor that expresses vascular endothelial growth factor, a key regulator of angiogenesis and tumor blood vessel permeability. Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor and the growth of gliomas. Bevacizumab monotherapy has proven effective for recurrent glioblastoma, and it extended progression-free survival and improved patient quality of life in various clinical trials. ⋯ However, these events are also associated with glioma itself, and careful attention needs to be paid to these events. Bevacizumab is used to treat various diseases including radiation necrosis and recurrent brain tumors such as brain metastases, schwannoma and meningioma, but additional clinical trials are necessary. The efficacy and current problems associated with bevacizumab in the treatment of glioblastoma and other brain tumors are reviewed.
-
Jpn. J. Clin. Oncol. · Apr 2013
ReviewProposal for the breakdown of increased cancer healthcare cost and its improvement.
Technological progress in the field of cancer treatment can be expected to accelerate in the future, giving hope to such patients. At the same time, there is concern that cancer care will become more expensive. ⋯ The Cancer Control Act was enacted in 2007 to promote work on cancer control using all the resources of the nation, and this should surely entail financial support. In order to take advantage of innovations in cancer care, reform of the payment system to lighten the economic burden of the patient would be a pressing necessity.